Top 3 drug approvals in September: Keytruda^®, Ibrance^® and Ezharmia^®

In the month of September there were several noteworthy drug approvals, meaning that more treatment options became available for patients mainly in the UK and Japan. Read on to find out about the approval of the first EZH1/2 dual inhibitor anywhere in the world as well as the approvals in the UK for treating melanoma and breast cancer. Keytruda® (pembrolizumab) Approved: 23 September 2022 Approving body: NICE Indication: Stage IIB and IIC melanoma This month the infamous drug Keytruda®(pembrolizumab) won yet another approval, this time in the UK to treat Stage IIB and IIC melanoma as an adjuvant treatment for...